Regorafenib as second-line therapy in hepatocellular carcinoma

被引：25
|
作者：
Duffy, Austin G. [1 ]
Greten, Tim F. [1 ]
机构：
[1] NCI, Gastrointestinal Malignancy Sect, Thorac & Gastrointestinal Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2017年 / 14卷 / 03期
关键词：
SORAFENIB;
D O I：
10.1038/nrgastro.2017.7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Drug development in hepatocellular carcinoma had essentially stalled since 2008 when sorafenib was established as the modest standard of care. Now, a positive result in a phase III study evaluating regorafenib challenges us to weigh its clinical significance as well as its real-world benefits and potential harms.
引用
收藏
页码：141 / 142
页数：2
相关论文
共 50 条
  • [41] Regorafenib combined with transarterial chemoembolization and PD-1 antibody as a second-line therapy for hepatocellular carcinoma: A real-world study.
    Pan, Tao
    Huang, Mingsheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16167 - E16167
  • [42] Second-line therapy for advanced colorectal carcinoma
    Starling N.
    Cunningham D.
    [J]. Current Oncology Reports, 2005, 7 (3) : 173 - 180
  • [43] Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
    Sugimoto, Rie
    Motomura, Kenta
    Ooho, Aritsune
    Aratake, Yoshifusa
    Ueda, Akihiro
    Senju, Takeshi
    Tanaka, Yuki
    Yada, Masayoshi
    Tanaka, Kohsuke
    Kuwano, Akifumi
    Morita, Yuusuke
    Nagasawa, Shigehiro
    Ooe, Mari
    Mutsuki, Taiji
    Yoshimoto, Tsuyoshi
    Yamashita, Naoki
    Nakashima, Mai
    Hioki, Tomonobu
    Koyanagi, Toshimasa
    Higuchi, Nobito
    Nakamura, Tsukasa
    Harada, Shigeru
    Tanaka, Masatake
    Tada, Seiya
    Satoh, Takeaki
    Uchimura, Koutarou
    Kuniyoshi, Masami
    Nakamuta, Makoto
    Kohjima, Motoyuki
    [J]. INTERNAL MEDICINE, 2022, 61 (21) : 3157 - 3164
  • [44] Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
    Shao, Y. -Y.
    Chen, B. -B.
    Ou, D. -L.
    Lin, Z. -Z.
    Hsu, C. -H.
    Wang, M. -J.
    Cheng, A. -L.
    Hsu, C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (08) : 722 - 730
  • [45] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    [J]. LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [46] Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study
    Bitzer, Michael
    Horger, Marius
    Giannini, Edoardo G.
    Ganten, Tom M.
    Woerns, Marcus A.
    Siveke, Jens T.
    Dollinger, Matthias M.
    Gerken, Guido
    Scheulen, Max E.
    Wege, Henning
    Zagonel, Vittorina
    Cillo, Umberto
    Trevisani, Franco
    Santoro, Armando
    Montesarchio, Vincenzo
    Malek, Nisar P.
    Holzapfel, Julia
    Herz, Thomas
    Ammendola, Astrid S.
    Pegoraro, Stefano
    Hauns, Bernhard
    Mais, Anna
    Lauer, Ulrich M.
    Henning, Stefan W.
    Hentsch, Bernd
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (02) : 280 - 288
  • [47] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    [J]. PLOS ONE, 2024, 19 (04):
  • [48] Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Ma, Jennifer
    O'Reilly, Eileen Mary
    Gansukh, Bolorsukh
    Chou, Joanne F.
    Capanu, Marinela
    Saltz, Leonard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [49] Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
    Kaseb, Ahmed O.
    Morris, Jeffrey S.
    Iwasaki, Michiko
    Al-Shamsi, Humaid O.
    Raghav, Kanwal Pratap Singh
    Girard, Lauren
    Cheung, Sheree
    Van Nguyen
    Elsayes, Khaled M.
    Xiao, Lianchun
    Abdel-Wahab, Reham
    Shalaby, Ahmed S.
    Hassan, Manal
    Hassabo, Hesham M.
    Wolff, Robert A.
    Yao, James C.
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 773 - 780
  • [50] A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma
    Delos Santos, S.
    Udayakumar, S.
    Nguyen, A.
    Ko, Y. J.
    Berry, S.
    Doherty, M.
    Chan, K. K. W.
    [J]. CURRENT ONCOLOGY, 2020, 27 (06) : 300 - 306
12345